Author + information
- Received December 14, 2015
- Revision received March 7, 2016
- Accepted March 22, 2016
- Published online July 12, 2016.
- aDivision of National Heart and Lung Institute, Imperial College, London, United Kingdom
- bNetherhall Gardens, London, United Kingdom
- ↵∗Reprint requests and correspondence:
Dr. Desmond J. Sheridan, C/O Catherine Enright, Division of National Heart and Lung Institute, Guy Scadding Building, Royal Brompton Campus, Imperial College, London SW3 6NP, United Kingdom.
Evidence-based medicine (EBM) has a long history, but was revived in the early 1990s by a campaign mounted by a movement that took its name. The EBM movement focused attention on the need for greater objectivity in medical decision-making and led to the Cochrane Collaboration, which provides reviews of evidence on the basis of comparative research. Important limitations of EBM’s effect on medicine have also emerged. Failure to acknowledge the limitations of clinical trials and systematic reviews has limited their applicability to individual patients’ circumstances. An almost exclusive focus on drugs and devices has left vast areas of health care in an evidence vacuum. An overdependence on commissions for its research may have limited its independence in selecting what it investigates. EBM needs to widen its scope beyond drugs and devices to address many areas that often lack evidence at present, notably, health policy, management, and reforms.
Prof. Sheridan’s book, “Evidence Based Medicine: Best Practice or Restrictive Dogma,” is published by Imperial College Press. Prof. Julian has no relationships relevant to the contents of this paper to disclose.
- Received December 14, 2015.
- Revision received March 7, 2016.
- Accepted March 22, 2016.
- American College of Cardiology Foundation